Program
TQB2922
A development code. Also written as “TQB2922 injection (subcutaneous administration)”, “TQB2922 injection (subcutaneous injection)” and “TQB2922 Subcutaneous Injection”.
In Sino Biopharmaceutical's pipeline, EGFR/cMET双抗
. Its studies are mostly in Colorectal Neoplasms · Head and Neck Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 55 open or running | phase 2since Jun 23, 2025 | Dec 19, 2023 | Dec 2026phase 1 · NCT06188624 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2922
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2023First study: phase 1 study in Advanced CancerFirst studyNCT06188624 · 150 planned · China
- Jun 23, 2025Phase 2 study in RAS/BRAF Wild Type Colorectal CancerNCT07044908 · 72 planned · China
- Nov 20, 2025Phase 1 study in Advanced CancersNCT07260708 · 42 planned · China
- May 17, 2026Phase 2 study in Head and Neck NeoplasmsNCT07601204 · 128 planned · China
- Sep 16, 2026Phase 2 study in Colorectal NeoplasmsNCT07844187 · 64 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in Advanced CancerNCT06188624
- Aug 31, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07844187
- Feb 2029Primary completion: phase 2 study in Head and Neck NeoplasmsNCT07601204
- Dec 2029Primary completion: phase 1 study in Advanced CancersNCT07260708
TargetBeta
“EGFR/cMET双抗”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07844187Colorectal Neoplasms · China | 2 | Not yet recruiting | Aug 31, 2027 | 64 |
| NCT07601204Head and Neck Neoplasms · China | 2 | Not yet recruiting | Feb 2029 | 128 |
| NCT07260708Advanced Cancers · China | 1 | Recruiting | Dec 2029 | 42 |
| NCT07044908RAS/BRAF Wild Type Colorectal Cancer · China | 2 | Recruiting | Jul 2026 | 72 |
| NCT06188624Advanced Cancer · China | 1 | Recruiting | Dec 2026 | 150 |
How it is read
Names in the registry
- “TQB2922 injection (subcutaneous administration)”, 1 entry
- “TQB2922 injection (subcutaneous injection)”, 1 entry
- “TQB2922 Subcutaneous Injection”, 1 entry
- “TQB2922 injection ± TAS-102 tablets”, 1 entry
- “TQB2922 injection+TAS-102 tablets ± Bevacizumab”, 1 entry
Codes read as this program: TQB2922.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 2 studies
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.